Skip to content

Vaccine patent waiver breaks faith with American companies, stifles innovation NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver, breaks faith with American innovators, punishes the ingenuity of our life sciences industry and will delay the…

Read More

BIO President and CEO Dr. Michelle McMurry-Heath sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on.

Read More